康宁杰瑞制药-B股票11月28日出现7.37%的盘中大跌,引发市场关注。
根据相关报导,分析称公司主要产品销售可能短期承压,机构将其明年收入预测大幅下调。报告表示,行业合规整治影响恩维达销售、部分在研药物上市节奏推迟,导致下调公司2025年收入预测至4.50亿元。同时机构还下调了恩维达和KN046的经POS调整销售峰值。
作为一家从事生物制药业务的上市公司,康宁杰瑞主要研发和销售肿瘤免疫类药物。如果主力产品销售短期承压,可能会严重影响其营收和现金流,令投资者对公司未来前景产生担忧。综合而言,公司产品销售前景欠佳或是导致本次股价大跌的主要原因。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.